Vertex appoints Ken Horton as executive vp and chief legal officer


Nancy Wysenski retires as chief commercial officer

Vertex Pharmaceuticals, a drug developer with sites in the US, UK and Canada, has made two changes to its executive team.

Kenneth Horton has become chief legal officer, where he will take on the additional title of executive vice president. The current incumbent, Ty Howton, will work with Horton over the coming months to ensure a smooth transition.

The company has also announced that Nancy Wysenksi, chief commercial officer, will retire. She joined Vertex in 2009 and built the company's first commercial team to support the approval and launch of its first medicines. A search for her replacement is ongoing.

Jeffrey Leiden, chairman, president and ceo, said: ‘Ken brings to Vertex more than 20 years of broad experience, with a focus on managing legal and compliance functions for large global healthcare companies, most recently as general counsel at MDS.

Sign up for your free email newsletter

‘I am pleased to welcome him to our team and would also like to thank both Nancy and Ty for their commitment to Vertex over the past several years.’